HC Wainwright Analysts Give Ohr Pharmaceuticals, Inc. (OHRP) a $10.00 Price Target
Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) has been given a $10.00 price target by investment analysts at HC Wainwright in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.
Separately, Zacks Investment Research raised Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Tuesday, July 18th.
Shares of Ohr Pharmaceuticals (NASDAQ OHRP) opened at 0.61 on Wednesday. Ohr Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $4.05. The stock has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.77. The company’s market capitalization is $34.29 million.
Ohr Pharmaceuticals (NASDAQ:OHRP) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.18. On average, analysts predict that Ohr Pharmaceuticals will post ($0.95) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Analysts Give Ohr Pharmaceuticals, Inc. (OHRP) a $10.00 Price Target” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/16/hc-wainwright-analysts-give-ohr-pharmaceuticals-inc-ohrp-a-10-00-price-target.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. acquired a new position in Ohr Pharmaceuticals during the first quarter worth $1,175,000. Sabby Management LLC increased its stake in Ohr Pharmaceuticals by 30.5% in the first quarter. Sabby Management LLC now owns 1,509,315 shares of the biotechnology company’s stock valued at $1,253,000 after buying an additional 352,922 shares during the period. Cannell Peter B & Co. Inc. purchased a new stake in Ohr Pharmaceuticals during the second quarter valued at about $187,000. Knoll Capital Management LP purchased a new stake in Ohr Pharmaceuticals during the third quarter valued at about $568,000. Finally, Renaissance Technologies LLC increased its stake in Ohr Pharmaceuticals by 242.3% in the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 162,600 shares during the period. 8.31% of the stock is currently owned by institutional investors and hedge funds.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.